Southern Nevada Cancer Research Foundation

TREATMENT PROTOCOLS

	BRAIN
	BREAST
	GASTROINTESTINAL
	GENITOURINARY
	GYNECOLOGICAL
	HEAD AND NECK
	HEMATOLOGICAL
	LUNG
	LYMPHOMA
	MELANOMA
	MYELOMA
	OTHER

HOME

BRAIN

	0320 - A PHASE III TRIAL COMPARING WHOLE BRAIN RADIATION AND STEREOTACTIC RADIOSURGERY ALONE VERSUS WITH TEMOZOLOMIDE OR ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND 1-3 BRAIN METASTASES
	0614 - A RANDOMIZED, PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MEMANTINE FOR PREVENTION OF COGNITIVE DYSFUNCTION IN PATIENTS RECEIVING WHOLE-BRAIN RADIOTHERAPY

BREAST

ADJUVANT

	40101 - Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Randomized Study
	369901 - OBSERVATIONAL COHORT STUDY: CHEMOTHERAPY DECISIONS AND OUTCOMES IN WOMEN AGE 65 OR OLDER WITH OPERABLE, NEWLY DIAGNOSED BREAST CANCER
	S0221- PHASE III TRIAL OF CONTINUOUS SCHEDULE AC + G VS. Q 2 WEEK SCHEDULE AC, FOLLOWED BY PACLITAXEL GIVEN EITHER EVERY 2 WEEKS OR WEEKLY FOR 12 WEEKS AS POST-OPERATIVE ADJUVANT THERAPY IN NODE-POSITIVE OR HIGH -RISK NODE NEGATIVE BREAST CANCER
	B-39/0413 - A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
	Z1031 - A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
	pacct-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The *TAILORx* Trial
	b-42 - A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting on an Aromatase Inhibitor (AI) or Tamoxifen Followed by and AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

METASTATIC

	S0226 - PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMEN WITH METASTATIC BREAST CANCER
	B-37 - A RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY FOR RADICALLY RESECTED LOCO-REGIONAL RELAPSE OF BREST CANCER
	A6181094 - A Phase 3 Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-line Advanced Disease Setting in Patients Having Breast Cancer
	40302 - Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer
	toc4129g - A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer

efc6596 - A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) at 90 mg/m2 every 3 weeks Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previously Treatment with a Gemcitabine-Containing Regimen

REGISTRY

CSTI5721BUS227 - Gastrointestinal Stromal Tumors (GIST) Registry Protocol

Back to Top

GENITOURINARY

BLADDER

0524 - A PHASE I/II TRIAL OF A COMBINATION OF PACLITAXEL AND TRASTUZUMAB WITH DAILY IRRADIATION OR PACLITAXEL ALONE WITH DAILY IRRADIATION FOLLOWING TRANSURETHRAL SURGERY FOR NON-CYSTECTOMY CANDIDATES WITH MUSCLE-INVASIVE BLADDER CANCER

RENAL

	E2805 - A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
	E4805 - A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma

PROSTATE

	9594 - INTERMITTENT ANDROGEN DEPRIVATION IN PATIENTS WITH STAGE D2 PROSTATE CANCER, PHASE III
	0232 - A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH INTERMEDIATE RISK PROSTATIC CARCINOMA
	90202 - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY OF EARLY VERSUS STANDARD ZOLEDRONIC ACID TO PREVENT SKELETAL RELATED EVENTS IN MEN WITH PROSTATE CANCER METASTATIC TO BONE
	P-0126 - A PHASE III RANDOMIZED STUDY OF HIGH DOSE 3D-CRT/IMRT VERSUS STANDARD DOSE3D-CRT/IMRT IN PATIENTS TREATED FOR LOCALIZED PROSTATE CANCER
	0521 - A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND 3DCRT/IMRT VS AS AND 3DCRT/IMRT FOLLOWED BY CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
	0518 - A Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
	0415 - A PHASE III RANDOMIZED STUDY OF HYPOFRACTIONATED 3D-CRT/IMRT VERSUS CONVENTIONALLY FRACTIONATED 3D-CRT/IMRT IN PATIENTS WITH FAVORABLE-RISK PROSTATE CANCER
	90203 - A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
	E3805 - CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer
	S0421 - PHASE III STUDY OF DOCETAXEL AND ATRASENTAN VERSUS DOCETAXEL AND PLACEBO FOR PATIENTS WITH ADVANCED HORMONE REFRACTORY PROSTATE CANCER
	0534 - A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Nodes or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
	EFC6546 - A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept versus Placebo administered every 3 weeks in patients treated with Docetaxel/Prednisone for metastatic Androgen-Independent Prostate Cancer

TESTIS

Back to Top

GYNECOLOGICAL

OVARIAN

CERVICAL

0417 - A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma

UTERINE

ENDOMETRIAL

0209 - A RANDOMIZED PHASE III TRIAL OF DOXORUBICIN/CISPLATIN/PACLITAXEL AND G-CSF VERSUS CARBOPLATIN/PACLITAXEL IN PATIENTS WITH STAGE III & IV OR RECURRENT ENDOMETRIAL CANCER

Back to Top

HEAD AND NECK

	E1302 - Phase III randomized, placebo controlled, trial of docetaxel versus docetaxel plus ZD1839 (Iressa, ZD1839 (Iressa, gefitinib)) in performance status 2 or previously treated patients with recurrent or metastatic head and neck cancer
	0522 - A Randomized Phase III Trial Of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III And IV Head And Neck Carcinomas
	0615 - A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer

Back to Top

HEMATOLOGICAL

S0106 - A PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG^®) DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION WITH DAUNOMYCIN AND CYTOSINE ARABINOSIDE FOLLOWED BY CONSOLIDATION AND SUBSEQUENT RANDOMIZATION TO POST-CONSOLIDATION THERAPY WITH GEMTUZUMAB OZOGAMICIN (MYLOTARG^®) OR NO ADDITIONAL THERAPY FOR PATIENTS UNDER AGE 56 WITH PREVIOUSLY UNTREATED DE NOVO ACUTE MYELOID LEUKEMIA (AML)

E2902 - A PHASE III RANDOMIZED STUDY OF FARNESYL TRANSFERASE INHIBITOR R115777 IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN SECOND OR SUBSEQUENT REMISSION OR IN REMISSION AFTER PRIMARY INDUCTION FAILURE

Back to Top

LUNG

NON-SMALL CELL

	0320 - A PHASE III TRIAL COMPARING WHOLE BRAIN RADIATION AND STEREOTACTIC RADIOSURGERY ALONE VERSUS WITH TEMOZOLOMIDE OR ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND 1-3 BRAIN METASTASES
	DMS 0410 - A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in patients with Inoperable Stage III Non-Small Cell Lung Cancer
	CYC202-06-14 - A Phase IIb Randomized Study of Oral Seliciclib in Patients with Previously Treated Non-Small Cell Lung Cancer
	0617 - A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGH-DOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER
	a6181087 - A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy and Safety Study of Sunitinib (SU011248) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Erlotinib
	30406 - A PHASE II RANDOMIZED STUDY OF OSI-774 (ERLOTINIB) WITH OR WITHOUT CARBOPLATIN/PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED ADENOCARCINOMA OF THE LUNG WHO NEVER SMOKED OR WERE FORMER LIGHT SMOKERS
	30607 - Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

SMALL CELL

30610 - Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Ciplatin and Etoposide

Back to Top

LYMPHOMA

HODGKIN'S

NON-HODGKIN'S

	E4402 - RANDOMIZED PHASE III TRIAL COMPARING TWO DIFFERENT RITUXIMAB DOSING REGIMENS FOR PATIENTS WITH LOW TUMOR BURDEN INDOLENT NON-HODGKIN'S LYMPHOMA
	50303 - Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas

	E1A06 - An Intergroup Phase III Randomized controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
	E1A05 - Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade^®)- Lenalidomide (Revlimid^®) -Dexamethasone (VRD) versus Bortezomib (Velcade^®) -Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen

	80405 - A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
	AVF3991n - AN OBSERVATIONAL STUDY OF AVASTIN^â (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF METASTATIC OR LOCALLY ADVANCED AND UNRESECTABLE COLORECTAL CANCER, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG (EXCLUDING PREDOMINANT SQUAMOUS CELL HISTOLOGY), OR LOCALLY RECURRENT OR METASTATIC BREAST CANCER
	s0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX
	EFC5505 - A multicenter randomized double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin / 5-FU/ LV
	shh4429g - A Randomized, Placebo-Controlled Phase II Study of GDC-0449 (Systemic Hedgehog Antagonist) with Concurrent Chemotherapy and Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer

	NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
	E5202 - Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

	80302 - A PHASE II TRIAL OF PREOPERATIVE IRINOTECAN, CISPLATIN AND RADIATION IN ESOPHAGEAL CANCER
	80403 - Randomized Phase II Study of ECF-C, IC-C or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer
	0436 - A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

	R-04 - A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
	E5204 - INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOVORIN AND BEVACIZUMAB FOR PATIENTS WITH STAGE II OR III RECTAL CANCER RECEIVING PRE-OPERATIVE CHEMORADIATION
	0822 - A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT) IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER